BB Biotech’s Theravance Biopharma TBPH Stock Holding History

BB Biotech’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-359,190	Closed	-$4.68M	–	30
2015 Q2	$4.68M	Buy	+359,190	New	+$5.57M	0.13%	29

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FAM

Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return

BB Biotech's TBPH Position: Q3 2015 in Review

BB Biotech sold out of Theravance Biopharma (TBPH) in Q3 2015, closing a stake of 359,190 shares — an estimated $4.68M sold.

BB Biotech first reported a position in TBPH in Q2 2015 and held it in 1 quarter. The position peaked at $4.68M in Q2 2015. 83 funds tracked by Wall St. Rank hold TBPH as of Q3 2015.

BB Biotech reported no remaining Theravance Biopharma position as of Q3 2015 after selling out during the quarter.
BB Biotech sold 359,190 Theravance Biopharma shares in Q3 2015, an estimated $4.68M.
BB Biotech first reported a position in Theravance Biopharma in Q2 2015 and held it in 1 quarter.
BB Biotech's Theravance Biopharma position peaked at $4.68M in Q2 2015.
83 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2015.

Based on BB Biotech's 13F filing for Q3 2015, filed 12 Nov 2015.